Parag Chokshi, MD
Gastroenterology · Sun City, AZNPI 1144243510
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,769 of the $5,058 with a category attached, or 74.5%. 31 manufacturers reported payments, led by Sanofi at 34.8% of the total.
Across 194 payments — averaging $26.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$2K
- AbbVie$974
- Johnson & Johnson$347
- Pfizer$275
- Regeneron Healthcare Solutions, Inc.$237
- Bristol Myers Squibb$219
- plus $1K from 25 others
Across 149 payments — averaging $3757.07 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$222K
- Pfizer$153K
- Takeda Pharmaceuticals U.S.A., Inc.$94K
- Bausch Health US, LLC$91K
What the payments were for
- Speaking & faculty fees$1,20024%
- Food & beverage$3,76975%
- Education$892%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 22 | $1,762 |
| AbbVie(2 entities) | 54 | $974 |
| Johnson & Johnson | 20 | $347 |
| Pfizer | 16 | $275 |
| Regeneron Healthcare Solutions, Inc. | 7 | $237 |
| Bristol Myers Squibb | 11 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $138 |
| Organon | 5 | $113 |
| Gilead | 5 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $98 |
| Merck | 5 | $82 |
| Ironwood Pharmaceuticals, Inc | 4 | $73 |
| Ardelyx, Inc. | 3 | $66 |
| Ferring Pharmaceuticals Inc. | 3 | $62 |
| Aimmune Therapeutics, Inc. | 3 | $58 |
| Madrigal Pharmaceuticals | 2 | $56 |
| UCB, Inc. | 2 | $52 |
| Intercept Pharmaceuticals, Inc. | 2 | $46 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Fresenius Kabi USA, LLC | 2 | $36 |
| Celltrion USA Inc. | 2 | $33 |
| Shionogi Inc | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $20 |
| Laborie Medical Technologies Corp. | 1 | $19 |
| Boehringer Ingelheim | 1 | $17 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Braintree Laboratories, Inc. | 1 | $14 |
| Sandoz | 1 | $14 |
| Medtronic | 1 | $14 |
| QOL Medical, LLC | 1 | $11 |
How this compares
$5,058 in reported general payments places this provider in the 55th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 16 | $52,083 |
| LinzessLinaclotide | 18 | $22,495 |
| Mesalamine | 19 | $7,185 |
| Omeprazole | 488 | $6,715 |
| Dicyclomine Hcl | 228 | $6,531 |
| Pantoprazole Sodium | 366 | $6,283 |
| Mesalamine ErMesalamine | 13 | $6,181 |
| Ursodiol | 38 | $5,838 |
| Famotidine | 173 | $2,162 |
| Ondansetron OdtOndansetron | 55 | $1,855 |
| Esomeprazole Magnesium | 41 | $1,147 |
| Sucralfate | 20 | $1,090 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 23 | $950 |
| Lansoprazole | 21 | $755 |
| Ondansetron Hcl | 21 | $660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $974 | $74,57834 claims |
| SandozLansoprazole | $14 | $75521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Sun City
- Chirag TrivediSun City$400K
- Keng-Yu ChuangSun City$14K
- Joel BrillParadise Valley$847K
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Neil SharmaGilbert$405K
- David LeffMesa$377K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.